Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Luis Javier Doncel-Vecino"'
Autor:
Carlos Antonio Aranda-López, Luis Javier Doncel-Vecino, Alejandra Vaello-Paños, Ángel Morales-Martínez de Tejada, Javier Pérez-Cervera, Miguel Sánchez-Sánchez, Gema Delgado-Expósito, Eugenio Dávila-Dávila
Publikováno v:
J Cardiol Cases
Herein is described the case of a 39-year-old female agronomist who was admitted to hospital after a syncopal episode. She had had fever, abdominal pain, nausea, and vomiting for the previous month. The patient showed signs of hypoperfusion, so a tra
Autor:
Juan Manuel Nogales-Asensio, Luis Javier Doncel-Vecino, José Francisco Díaz-Fernández, José Moreu-Burgos, José R. López-Mínguez, Pedro Martínez-Romero, José Antonio Fernández-Díaz, Antonio Merchán-Herrera, Francisco Pomar-Domingo, Raúl Valdesuso-Aguilar
Publikováno v:
Revista Española de Cardiología. 67:522-530
Introduccion y objetivos Hasta un 25% de los pacientes sometidos a intervencionismo coronario percutaneo presentan alguna limitacion para la utilizacion de los stents farmacoactivos. Nuestro objetivo es evaluar si el stent bioactivo de titanio y oxid
Publikováno v:
Revista Española de Cardiología. 71:575
Publikováno v:
Revista Española de Cardiología (English Edition). 71:575
Autor:
José Ramón, López Mínguez, Juan Manuel, Nogales Asensio, Luis Javier, Doncel Vecino, Jorge, Sandoval, Sebastián, Romany, Pedro, Martínez Romero, José Antonio, Fernández Díaz, Javier, Fernández Portales, Reyes, González Fernández, Ginés, Martínez Cáceres, Antonio, Merchán Herrera, Fernando, Alfonso Manterola, Alfredo, Gómez
Publikováno v:
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 10(1)
Aims: Paclitaxel drug-eluting balloons (pDEB) could be an attractive option to minimise side branch (SB) restenosis in bifurcated coronary lesions. We compared angiographic and clinical outcomes with pDEB plus bare metal stent (BMS) versus drug-eluti
Autor:
Antonio Merchán Herrera, Luis Javier Doncel Vecino, Nieves Moreno Sánchez, Juan Manuel Nogales Asensio, Celia Villar Mariscal, José R. López-Mínguez
Publikováno v:
International Journal of Cardiology. 114:E65-E67
Flecainide is an antiarrhythmic considered safe in patients who have no structural cardiopathy, and frequently used in the prevention of atrial fibrillation. However, in patients with a history of infarction and/or severe conduction disorders, its pr